The present invention concerns cobalamin derivatives of formula (I) ##STR00001##
wherein X is a ligand having a formula selected from among:
—(CH.sub.2).sub.1-5—S—(CH.sub.2).sub.0-3—CH.sub.3, —S—(CH.sub.2).sub.1-5—NH.sub.2 and ##STR00002##
further wherein R.sub.1 is H, methyl or ethyl, R.sub.2 is ##STR00003##
and R.sub.3 is —H or ##STR00004##
and its use in diseases caused by lack of vitamin B.sub.12 support.

The present invention concerns cobalamin derivatives of formula (I) ##STR00001##
wherein X is a ligand having a formula selected from among:
—(CH.sub.2).sub.1-5—S—(CH.sub.2).sub.0-3—CH.sub.3, —S—(CH.sub.2).sub.1-5—NH.sub.2 and ##STR00002##
further wherein R.sub.1 is H, methyl or ethyl, R.sub.2 is ##STR00003##
and R.sub.3 is —H or ##STR00004##
and its use in diseases caused by lack of vitamin B.sub.12 support.

The present disclosure provides 3′ protected nucleotides, including those 3′ protected nucleotides having a detectable tag. Systems and methods of sequencing nucleic acids using the 3′ protected nucleotides are also disclosed, such as the sequencing of a nucleic acid using a nanopore or the sequencing of a nucleic acid via sequencing-by-synthesis.

Compounds useful for forming nucleic acids having the structure of Formula I:

##STR00001##

Each of R.sup.1 or R.sup.2 is independently selected from hydrogen, a protecting group, or a phosphoramidite group. R.sup.3 is selected from H, F, O—C.sub.1-6 alkyl, O-MOE and a removable hydroxyl-protecting group. Q is a heterocyclic base. R.sup.4 is a cyclic hydrocarbon. Also disclosed are processes for forming the nucleic acids from the compounds and the nucleic acid products produced.

Compounds useful for forming nucleic acids having the structure of Formula I:

##STR00001##

Each of R.sup.1 or R.sup.2 is independently selected from hydrogen, a protecting group, or a phosphoramidite group. R.sup.3 is selected from H, F, O—C.sub.1-6 alkyl, O-MOE and a removable hydroxyl-protecting group. Q is a heterocyclic base. R.sup.4 is a cyclic hydrocarbon. Also disclosed are processes for forming the nucleic acids from the compounds and the nucleic acid products produced.

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

A construct composed of a Kinesin-derived Angiogenesis Inhibitor peptide and one or more carrier moieties and/or stabilizing moieties is provided as are methods for inhibiting angiogenesis and treating a disease or condition characterized by excessive vascularity.

A construct composed of a Kinesin-derived Angiogenesis Inhibitor peptide and one or more carrier moieties and/or stabilizing moieties is provided as are methods for inhibiting angiogenesis and treating a disease or condition characterized by excessive vascularity.

The present invention is directed to assay methods and compounds and kits used in such assays.